Remove 2024 Remove Insurance Remove Packaging
article thumbnail

The European Market Access Lag: 2021–2024

Pharmaceutical Technology

On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. First, the access landscape for 220 originator medicines approved by the EMA between 2021–2024 was assessed. Reimbursement status for each brand per European market was analysed during this period.

52
article thumbnail

Canadian pharmacy Ozempic: Cost, availability & more

The Checkup by Singlecare

However, it can also be expensive, which has sent many people on a mission to save money, particularly if they don’t have insurance coverage. Without insurance , a 30-day supply of 1 mg doses costs $1,322.61 For example, she says many insurance plans will not cover Ozempic for weight loss, although some may cover Wegovy instead.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SCHOTT Pharma invests in RTU cartridge capacity expansion

Pharmaceutical Technology

In June 2024, the company opened a new facility at the same site, which has already begun producing high-quality prefillable glass syringes. By GlobalData Learn more about Strategic Intelligence SCHOTT Pharma CEO Andreas Reisse stated: “To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields.

article thumbnail

Can you take DayQuil with amoxicillin?

The Checkup by Singlecare

The FDA followed this up in 2024 by proposing that products like DayQuil Cold and Flu stop using phenylephrine. Generic amoxicillin is typically covered by insurance, but OTC DayQuil is often not covered. Without insurance, their prices are fairly comparable. DayQuil Cough syrup is priced similarly at $14 for 1, 354 mL bottle.

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

Give your business an edge with our leading industry insights.

article thumbnail

EC authorises Sydnexis’ paediatric myopia treatment

Pharmaceutical Technology

Give your business an edge with our leading industry insights.

article thumbnail

Aytu BioPharma to commercialise Exxua for MDD in the US

Pharmaceutical Technology

Give your business an edge with our leading industry insights.

52